Prelude Therapeutics Inc (PRLD) - Dilution Analysis

10-Q filing | 82.5M shares outstanding

10-K filing | 63.0M shares outstanding

S-3 filing: Prelude Therapeutics Incorporated is offering 6,250,000 shares of common stock by the selling stockholder.

10-Q filing | 56.5M shares outstanding

10-K filing | 55.2M shares outstanding

10-Q filing | 55.0M shares outstanding

10-Q filing | 55.0M shares outstanding

S-3 filing: Prelude Therapeutics Incorporated is offering common stock, preferred stock, debt securities, warrants, subscription rights and units up to an aggregate amount of $400,000,000.

10-Q filing | 54.9M shares outstanding

S-3/A filing: This is an S-3/A filing for a shelf offering of common stock. The filing details estimated expenses for the issuance and distribution of shares and discusses indemnification of directors and officers.

S-3 filing: The filing relates to the offer and resale of up to 7,936,759 shares of Prelude Therapeutics Incorporated common stock by the selling stockholders.

10-K filing | 60.4M shares outstanding

8-K filing: Prelude Therapeutics Incorporated entered into a securities purchase agreement with institutional accredited investors to issue and sell pre-funded warrants to purchase up to 7,936,759 shares of common stock at a price of $3.1499 per warrant with an exercise price of $0.0001 per share, with expected net proceeds of approximately $24.9 million. ($24.9M proceeds)

10-Q filing | 54.8M shares outstanding

10-Q filing | 56.2M shares outstanding

10-Q filing | 47.7M shares outstanding

10-K filing | 47.4M shares outstanding

10-Q filing | 47.4M shares outstanding

10-Q filing | 47.3M shares outstanding

10-Q filing | 47.7M shares outstanding

10-K filing | 47.6M shares outstanding

S-3 filing: This is an S-3 filing for Prelude Therapeutics Incorporated for offering of Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units, with a total proposed amount of $400,000,000 and 31,574,631 shares of Common Stock offered by the Selling Stockholders.

10-Q filing | 47.2M shares outstanding

10-Q filing | 47.1M shares outstanding

10-Q filing | 47.0M shares outstanding

10-K filing | 46.6M shares outstanding

S-1 filing: S-1 filing for a common stock offering with an option to purchase additional shares.

10-Q filing | 43.7M shares outstanding

S-1/A filing: This S-1/A filing outlines the company's initial public offering, detailing the proposed offering of common stock, the option for underwriters to purchase additional shares, and the intended use of proceeds for clinical development and general corporate purposes.

S-1/A filing: This S-1/A filing relates to a company offering common stock, with an option for underwriters to purchase additional shares, and outlines the use of proceeds for clinical development and other corporate purposes.

S-1 filing: This S-1 filing outlines a proposed offering of common stock, including an option for underwriters to purchase additional shares, and details the company's financial data and plans for the use of proceeds.